Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
Open accessThe DOI matches its Crossref record; 119 of the 121 references it cites were found in a registry or an index.
Abstract
The use of low-density lipoprotein cholesterol (LDL-C)-lowering medications has led to a significant reduction of cardiovascular risk in both primary and secondary prevention. Statin therapy, one of the cornerstones for the prevention and treatment of cardiovascular disease (CVD), has been demonstrated to be effective in lowering LDL-C levels and in reducing the risk for CVD and is generally well-tolerated. However, compliance with statins remains suboptimal. One of the main reasons is limitations by adverse events, notably myopathies, which can lead to non-compliance with the prescribed statin regimen. Reducing the burden of elevated LDL-C levels is critical in patients with CVD as well as in patients with very high baseline levels of LDL-C (e.g. patients with familial hypercholesterolaemia), as statin therapy is insufficient for optimally reducing LDL-C below target values. In this review, we discuss alternative treatment options after maximally tolerated doses of statin therapy, including ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and cholesteryl ester transfer protein (CETP) inhibitors. Difficult-to-treat patients may benefit from combination therapy with ezetimibe or a PCSK9 inhibitor (evolocumab or alirocumab, which are now available). Updates of treatment guidelines are needed to guide the management of patients who will best benefit from these new treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Trafficking of LDLR in the presence of PCSK9 (a) or following PCSK9 inhibition by a monoclonal antibody (b). a Secreted PCSK9 binds to LDLR on the liver cell surface and mediates the lysosomal degradation of the complex formed by PCSK9, LDLR, and LDL [68]. b In the presence of a monoclonal antibody that binds to PCSK9, the PCSK9-mediated degradation of LDLR is inhibited, resulting in an increased uptake of LDL-cholesterol by LDLR as more LDLR are recycled at the cell surface [72]. LDL low-density lipoprotein, LDLR low-density lipoprotein receptor, PCSK9 proprotein convertase subtilisin/kexin type 9](https://figures.cochat.ai/paper-figures/99fbd173f3c3431fb3ebcd58e134e201/unmet-needs-in-ldl-c-lowering-when-statins-wont-do-figure-1.jpg)
![Fig. 2 Impact of statins on cholesterol metabolism. Statins inhibit the biosynthesis of intracellular cholesterol by inhibiting HMG-CoA reductase. This results in low levels of intracellular cholesterol, leading to increased SREBP-2 activity, which promotes the production of PCSK9 and LDLR, the degradation of which is mediated by PCSK9 [72]. HMG CoA 3-hydroxy-3-methyl-glutaryl-CoA, LDL low-density lipoprotein, LDLR low density lipoprotein receptor, mRNA messenger RNA, PCSK9 proprotein convertase subtilisin/kexin type 9, SREBP-2 sterol-regulatory element-binding protein](https://figures.cochat.ai/paper-figures/aeafb13aac6a48b0b2884919e195edf0/unmet-needs-in-ldl-c-lowering-when-statins-wont-do-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a consequence, multiple authors have concluded that there is a significant unmet medical need for patients with dyslipidaemia to reduce blood lipid levels to prevent the incidence of adverse cardiovascular events [26–30].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary choice of statins works well due to their effectiveness and safety as well as affordability, but they fail to meet LDL-C goals or are poorly tolerated by patients [74–76].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [75]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491 · cited 1×
“Most guidelines use risk estimation systems based on either the Framingham or the SCORE projects [2, 14, 15].”
MethodThe metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290 · cited 1×
“Most guidelines use risk estimation systems based on either the Framingham or the SCORE projects [2, 14, 15].”
Method2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437741.48606.98 · Cited by 3,697
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181 · cited 7×
“Additionally, individuals with loss-of-function mutations in PCSK9 were found to have reduced plasma levels of LDLC and to be protected from CHD [69, 74].”
BackgroundInfluentialNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · cited 2×
“SEARCH Collaborative Group [53] (randomized trial of 12,064 pts who received simvastatin 20 or 80 mg daily) Rhabdomyolysis 49 cases of ‘definite myopathy’ in the simvastatin 80-mg group vs.”
MethodInfluentialStatins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381 · cited 5×
“Additionally, individuals with loss-of-function mutations in PCSK9 were found to have reduced plasma levels of LDLC and to be protected from CHD [69, 74].”
BackgroundInfluentialLong-term persistence in use of statin therapy in elderly patients
Benner, J. S. (2002) · JAMA · doi:10.1001/jama.288.4.455 · Cited by 1,232
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226 · cited 2×
“However, they are also least potent in LDL-C lowering, and statins associated with more aggressive LDL-C lowering might be expected to result in a higher risk of muscular adverse effects [40, 47].”
BackgroundCuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Rasmussen, J. N., Chong, A., & Alter, D. A. (2007) · JAMA · doi:10.1001/jama.297.2.177 · Cited by 975
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875 · cited 1×
“Higher incidences of rhabdomyolysis were reported with atorvastatin or cerivastatin therapy, both as monotherapy and in combination with fibrates [48].”
BackgroundBrugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792
Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civeira, F., Burgess, L., Langslet, G., Scott, R., Olsson, A. G., Sullivan, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61399-4 · Cited by 756
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749 · cited 1×
“Whereas dalcetrapib only increased HDL-C levels, torcetrapib (ILLUMINATE trial) [121], anacetrapib (DEFINE trial) [122], evacetrapib [123], and TA-8995 (TULIP trial) [124] also caused 14–45 % decreases in LDL-C.”
BackgroundCuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61731-0 · Cited by 744
Raal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R., Wasserman, S. M., & Stein, E. A. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61374-x · Cited by 734
Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism
Golomb, B. A., & Evans, M. A. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/0129784-200808060-00004 · Cited by 677
Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
Kastelein, J. J. P., van Leuven, S. I., Burgess, L., Evans, G. W., Kuivenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071359 · Cited by 658
Persistence of Use of Lipid-Lowering Medications: A Cross-National Study
Avorn, J., Monette, J., Lacour, A., Bohn, R. L., Monane, M., Mogun, H., & LeLorier, J. (1998) · JAMA · doi:10.1001/jama.279.18.1458 · Cited by 634
Impact of Medication Therapy Discontinuation on Mortality After Myocardial Infarction
Ho, P. M., Spertus, J. A., Masoudi, F. A., Reid, K. J., Peterson, E. D., Magid, D. J., Krumholz, H. M., & Rumsfeld, J. S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1842 · Cited by 633
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
Cuchel, M., Bloedon, L. T., Szapary, P. O., Kolansky, D. M., Wolfe, M. L., Sarkis, A., Millar, J. S., Ikewaki, K., Siegelman, E. S., Gregg, R. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061189 · Cited by 580
Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 577 · cited 1×
“The previously published phase I trial is the first example of therapeutic RNA interference in humans [77].”
BackgroundDiscontinuation of Statins in Routine Care Settings: A Cohort Study
Zhang, H., Plutzky, J., Skentzos, S., Morrison, F., Mar, P., Shubina, M., & Turchin, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-7-201304020-00004 · Cited by 548
Kastelein, J. J. P., Ginsberg, H. N., Langslet, G., Hovingh, G. K., Ceska, R., Dufour, R., Blom, D., Civeira, F., Krempf, M., Lorenzato, C., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv370 · Cited by 533
PCSK9: a convertase that coordinates LDL catabolism
Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800091-jlr200 · Cited by 533 · cited 2×
“This results in low levels of intracellular cholesterol, leading to increased SREBP-2 activity, which promotes the production of PCSK9 and LDLR, the degradation of which is mediated by PCSK9 [72].”
BackgroundAnti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Stroes, E., Colquhoun, D., Sullivan, D., Civeira, F., Rosenson, R. S., Watts, G. F., Bruckert, E., Cho, L., Dent, R., Knusel, B., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.019 · Cited by 526 · cited 1×
“Other therapies, such as bile acid sequestrants and nicotinic acid, have been evaluated but found to be poorly tolerated [79].”
BackgroundNissen, S. E., Stroes, E., Dent-Acosta, R. E., Rosenson, R. S., Lehman, S. J., Sattar, N., Preiss, D., Bruckert, E., Ceška, R., Lepor, N., et al. (2016) · JAMA · doi:10.1001/jama.2016.3608 · Cited by 522 · cited 1×
“Further evidence will come from outcome trials; for now, LDL-C is an accepted marker for lipid-lowering therapies, and these data should be used for future guideline updates [104].”
BackgroundEffect of statins on skeletal muscle function
Parker, B. A., Capizzi, J. A., Grimaldi, A. S., Clarkson, P. M., Cole, S. M., Keadle, J., Chipkin, S., Pescatello, L. S., Simpson, K., White, C. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.136101 · Cited by 500 · cited 1×
“9 %, respectively) [40, 46]; patients receiving lovastatin might have a high risk of SAMS [28]; and the lowest rates are described for patients receiving pravastatin and fluvastatin (10.”
BackgroundCohen, J. D., Brinton, E. A., Ito, M. K., & Jacobson, T. A. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.03.003 · Cited by 486
An assessment by the statin muscle safety task force: 2014 update
Rosenson, R. S., Baker, S. K., Jacobson, T. A., Kopecky, S. L., & Parker, B. A. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.03.004 · Cited by 485 · cited 4×
“In addition, several researchers have found that concurrent use of statins with fibrates or niacin significantly increases the risk of rhabdomyolysis compared with monotherapy, with a higher risk more often reported in statin–fibrate combinations than in statin–niacin combinations [35, 37, 38].”
BackgroundInfluentialRisk for Myopathy With Statin Therapy in High-Risk Patients
Ballantyne, C. M., Corsini, A., Davidson, M. H., Holdaas, H., Jacobson, T. A., Leitersdorf, E., März, W., Reckless, J. P. D., & Stein, E. A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.5.553 · Cited by 453 · cited 1×
“However, they are also least potent in LDL-C lowering, and statins associated with more aggressive LDL-C lowering might be expected to result in a higher risk of muscular adverse effects [40, 47].”
BackgroundSjouke, B., Kusters, D. M., Kindt, I., Besseling, J., Defesche, J. C., Sijbrands, E. J. G., Roeters van Lennep, J. E., Stalenhoef, A. F. H., Wiegman, A., de Graaf, J., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu058 · Cited by 443
Value and Limitations of Existing Scores for the Assessment of Cardiovascular Risk
Cooney, M. T., Dudina, A. L., & Graham, I. M. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.020 · Cited by 436
Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments
Mills, E. J., Rachlis, B., Wu, P., Devereaux, P. J., Arora, P., & Perri, D. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.039 · Cited by 423
Nicholls, S. J., Brewer, H. B., Kastelein, J. J. P., Krueger, K. A., Wang, M.-D., Shao, M., Hu, B., McErlean, E., & Nissen, S. E. (2011) · JAMA · doi:10.1001/jama.2011.1649 · Cited by 410 · cited 1×
“Whereas dalcetrapib only increased HDL-C levels, torcetrapib (ILLUMINATE trial) [121], anacetrapib (DEFINE trial) [122], evacetrapib [123], and TA-8995 (TULIP trial) [124] also caused 14–45 % decreases in LDL-C.”
BackgroundSchwartz, G. G., Bessac, L., Berdan, L. G., Bhatt, D. L., Bittner, V., Diaz, R., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.07.028 · Cited by 408 · cited 1×
“Firm evidence will be obtained by clinical outcome trials that will be concluded in the near future [105, 106].”
BackgroundCannon, C. P., Cariou, B., Blom, D., McKenney, J. M., Lorenzato, C., Pordy, R., Chaudhari, U., & Colhoun, H. M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv028 · Cited by 402
Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus
Besseling, J., Kastelein, J. J. P., Defesche, J. C., Hutten, B. A., & Hovingh, G. K. (2015) · JAMA · doi:10.1001/jama.2015.1206 · Cited by 387 · cited 1×
“Others showed that LDL interferes with insulin secretion in an LDLR-dependent manner [133, 134], and that patients with FH are at reduced risk of diabetes [135].”
BackgroundBanach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., et al. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.49807 · Cited by 378
Kavousi, M., Leening, M. J. G., Nanchen, D., Greenland, P., Graham, I. M., Steyerberg, E. W., Ikram, M. A., Stricker, B. H., Hofman, A., & Franco, O. H. (2014) · JAMA · doi:10.1001/jama.2014.2632 · Cited by 351 · cited 1×
“which has been a matter of debate [16, 17].”
BackgroundKereiakes, D. J., Robinson, J. G., Cannon, C. P., Lorenzato, C., Pordy, R., Chaudhari, U., & Colhoun, H. M. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.03.004 · Cited by 349
Predictors of Nonadherence to Statins: A Systematic Review and Meta-Analysis
Mann, D. M., Woodward, M., Muntner, P., Falzon, L., & Kronish, I. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1p150 · Cited by 329 · cited 2×
“There are many reasons for non-adherence, including age, sex, income, comorbidities, and complexity of regimen [24].”
BackgroundStein, E. A., Dufour, R., Gagne, C., Gaudet, D., East, C., Donovan, J. M., Chin, W., Tribble, D. L., & McGowan, M. (2012) · Circulation · doi:10.1161/circulationaha.112.104125 · Cited by 301
Thomas, G. S., Cromwell, W. C., Ali, S., Chin, W., Flaim, J. D., & Davidson, M. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.081 · Cited by 245
Hovingh, G. K., Kastelein, J. J. P., van Deventer, S. J. H., Round, P., Ford, J., Saleheen, D., Rader, D. J., Brewer, H. B., & Barter, P. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60158-1 · Cited by 239 · cited 1×
“Whereas dalcetrapib only increased HDL-C levels, torcetrapib (ILLUMINATE trial) [121], anacetrapib (DEFINE trial) [122], evacetrapib [123], and TA-8995 (TULIP trial) [124] also caused 14–45 % decreases in LDL-C.”
BackgroundLipid lowering with PCSK9 inhibitors
Dadu, R. T., & Ballantyne, C. M. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.84 · Cited by 237 · cited 2×
“The evidence from trials in these patients indicates that evolocumab might be an efficacious and tolerable option for them, a conclusion also drawn by Dadu and Ballantyne [78] in their review of lipid lowering with PCSK9 inhibitors.”
BackgroundRütti, S., Ehses, J. A., Sibler, R. A., Prazak, R., Rohrer, L., Georgopoulos, S., Meier, D. T., Niclauss, N., Berney, T., Donath, M. Y., et al. (2009) · Endocrinology · doi:10.1210/en.2009-0252 · Cited by 237 · cited 1×
“Others showed that LDL interferes with insulin secretion in an LDLR-dependent manner [133, 134], and that patients with FH are at reduced risk of diabetes [135].”
BackgroundResistance and intolerance to statins
Reiner, Ž. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.05.009 · Cited by 225 · cited 1×
“SAMS are usually defined as diffuse muscle symptoms that may or may not be accompanied by an elevation of plasma creatinine kinase (CK) activity [35, 36].”
BackgroundMcGowan, M. P., Tardif, J.-C., Ceska, R., Burgess, L. J., Soran, H., Gouni-Berthold, I., Wagener, G., & Chasan-Taber, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049006 · Cited by 224
SERUM CHOLESTEROL AND CANCER IN THE NHANES I EPIDEMIOLOGIC FOLLOWUP STUDY
Schatzkin, A., Taylor, P., Carter, C., Hoover, R., Ziegler, R., Larson, D., & Licitra, L. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90890-7 · Cited by 224
Cooney, M. T., Dudina, A., D'Agostino, R., & Graham, I. M. (2010) · Circulation · doi:10.1161/circulationaha.109.852756 · Cited by 222
Bays, H., Gaudet, D., Weiss, R., Ruiz, J. L., Watts, G. F., Gouni-Berthold, I., Robinson, J., Zhao, J., Hanotin, C., & Donahue, S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1520 · Cited by 221
Mendelian randomization studies in coronary artery disease
Jansen, H., Samani, N. J., & Schunkert, H. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu208 · Cited by 212 · cited 1×
“A particular advantage of the MR approach is that it can provide information on the impact of a lifetime modulation of a biomarker [67].”
BackgroundMeta-analysis of drug-induced adverse events associated with intensive-dose statin therapy
Silva, M., Matthews, M. L., Jarvis, C., Nolan, N. M., Belliveau, P., Malloy, M., & Gandhi, P. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.02.008 · Cited by 208 · cited 4×
“[51] (meta-analysis of RCTs) AEs leading to treatment discontinuation OR 1.”
BackgroundInfluentialLee, J., & Hegele, R. A. (2014) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-013-9665-4 · Cited by 202 · cited 1×
“Only patients with homozygous hypobetalipoproteinemia and patients with abetalipoproteinemia (because of mutations in MTP) with complete absence of apoB-containing lipoproteins experience severe neurological disease such as ataxia and retinitis pigmentosa [130].”
BackgroundVisser, M. E., Wagener, G., Baker, B. F., Geary, R. S., Donovan, J. M., Beuers, U. H. W., Nederveen, A. J., Verheij, J., Trip, M. D., Basart, D. C. G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs023 · Cited by 192
Farnier, M., Jones, P., Severance, R., Averna, M., Steinhagen-Thiessen, E., Colhoun, H. M., Du, Y., Hanotin, C., & Donahue, S. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.11.010 · Cited by 189
The Severe Hypercholesterolemia Phenotype
Sniderman, A. D., Tsimikas, S., & Fazio, S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.060 · Cited by 177 · cited 2×
“LDL-C levels in these patients are two- to threefold higher than normal [58, 59, 62, 63].”
BackgroundSabatine, M. S., Giugliano, R. P., Keech, A., Honarpour, N., Wang, H., Liu, T., Wasserman, S. M., Scott, R., Sever, P. S., & Pedersen, T. R. (2016) · American Heart Journal · doi:10.1016/j.ahj.2015.11.015 · Cited by 176 · cited 1×
“Firm evidence will be obtained by clinical outcome trials that will be concluded in the near future [105, 106].”
BackgroundA Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32
Varret, M., Rabès, J.-P., Saint-Jore, B., Cenarro, A., Marinoni, J.-C., Civeira, F., Devillers, M., Krempf, M., Coulon, M., Thiart, R., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302370 · Cited by 175
Mancini, G. B. J., Tashakkor, A. Y., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D. S., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.09.023 · Cited by 173 · cited 3×
“In addition, several researchers have found that concurrent use of statins with fibrates or niacin significantly increases the risk of rhabdomyolysis compared with monotherapy, with a higher risk more often reported in statin–fibrate combinations than in statin–niacin combinations [35, 37, 38].”
BackgroundNichols, G. A., & Koro, C. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.022 · Cited by 173
Toward “Pain-Free” Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia
Jacobson, T. A. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60897-5 · Cited by 168 · cited 3×
“In addition, several researchers have found that concurrent use of statins with fibrates or niacin significantly increases the risk of rhabdomyolysis compared with monotherapy, with a higher risk more often reported in statin–fibrate combinations than in statin–niacin combinations [35, 37, 38].”
BackgroundLinsel-Nitschke, P., Götz, A., Erdmann, J., Braenne, I., Braund, P., Hengstenberg, C., Stark, K., Fischer, M., Schreiber, S., El Mokhtari, N. E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002986 · Cited by 166 · cited 3×
“In this respect, MR studies demonstrated that frequent variants in the LDLR gene, which increase LDL-C as early as in childhood by 15 mg/dl, result in stronger effects on coronary artery disease risk than predicted by epidemiological or clinical studies for such a degree of LDL variability [68].”
BackgroundInfluentialMoriarty, P. M., Jacobson, T. A., Bruckert, E., Thompson, P. D., Guyton, J. R., Baccara-Dinet, M. T., & Gipe, D. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.09.007 · Cited by 154
Continuation of Statin Treatment and All-Cause Mortality: A Population-Based Cohort Study
Shalev, V., Chodick, G., Silber, H., Kokia, E., Jan, J., & Heymann, A. D. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.552 · Cited by 151 · cited 1×
“A number of large-scale clinical trials have demonstrated that statins substantially reduce cardiovascular morbidity and mortality in both primary and secondary prevention [3–7] and in high-risk patients [8].”
BackgroundSattar, N. A., Preiss, D., Robinson, J. G., Djedjos, C. S., Elliott, M., Somaratne, R. M., Wasserman, S. M., & Raal, F. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00003-6 · Cited by 146
Chodick, G., Shalev, V., Gerber, Y., Heymann, A. D., Silber, H., Simah, V., & Kokia, E. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.012 · Cited by 145 · cited 2×
“However, compliance remains suboptimal, even though long-term persistence with statin therapy is important for clinical benefits [10].”
BackgroundKruit, J. K., Kremer, P. H. C., Dai, L., Tang, R., Ruddle, P., de Haan, W., Brunham, L. R., Verchere, C. B., & Hayden, M. R. (2010) · Diabetologia · doi:10.1007/s00125-010-1691-2 · Cited by 141 · cited 1×
“Others showed that LDL interferes with insulin secretion in an LDLR-dependent manner [133, 134], and that patients with FH are at reduced risk of diabetes [135].”
BackgroundProof That Lower Is Better — LDL Cholesterol and IMPROVE-IT
Jarcho, J. A., & Keaney, J. F. (2015) · New England Journal of Medicine · doi:10.1056/nejme1507041 · Cited by 131 · cited 4×
“of the most important implications of this trial is that all reductions in LDL-C levels by enhanced hepatic LDL removal through the LDLR pathway are beneficial [65].”
BackgroundMethodInfluentialAn assessment by the Statin Diabetes Safety Task Force: 2014 update
Maki, K. C., Ridker, P. M., Brown, W. V., Grundy, S. M., & Sattar, N. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.02.012 · Cited by 119
Statins and Risk of New-Onset Diabetes Mellitus
Shah, R. V., & Goldfine, A. B. (2012) · Circulation · doi:10.1161/circulationaha.112.122135 · Cited by 106
The AKT/mTOR signaling pathway plays a key role in statin-induced myotoxicity
Bonifacio, A., Sanvee, G. M., Bouitbir, J., & Krähenbühl, S. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.04.010 · Cited by 103 · cited 1×
“the mevalonate–cholesterol pathway [131, 132].”
Self-citationStatin use and musculoskeletal pain among adults with and without arthritis
Buettner, C., Rippberger, M. J., Smith, J. K., Leveille, S. G., Davis, R. B., & Mittleman, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.007 · Cited by 102
Zhang, L., McCabe, T., Condra, J. H., Ni, Y. G., Peterson, L. B., Wang, W., Strack, A. M., Wang, F., Pandit, S., Hammond, H., et al. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.3524 · Cited by 101 · cited 1×
“However, this co-regulation is counteractive, as the production of PCSK9 protein triggers LDLR protein trafficking for lysosomal degradation and results in an attenuated LDL-C-lowering effect of statins [75].”
BackgroundCombined therapy in the treatment of dyslipidemia
Reiner, Ž. (2010) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00764.x · Cited by 100 · cited 2×
“In these cases, combination therapy should be considered [70].”
BackgroundImpact of adherence to statins on coronary artery disease in primary prevention
Bouchard, M., Dragomir, A., Blais, L., Bérard, A., Pilon, D., & Perreault, S. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02828.x · Cited by 99
SERUM CHOLESTEROL AND CANCER IN THE NHANES I EPIDEMIOLOGICAL FOLLOW-UP STUDY
Kennedy, A., Schatzkin, A. G., Hoover, R. N., Taylor, P., Ziegler, R., & Carter, C. L. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91531-5 · Cited by 86
Blom, D. J., Djedjos, C. S., Monsalvo, M. L., Bridges, I., Wasserman, S. M., Scott, R., & Roth, E. (2015) · Circulation Research · doi:10.1161/circresaha.115.307071 · Cited by 84
Prevalence and risk factors of muscle complications secondary to statins
El‐Salem, K., Ababneh, B., Rudnicki, S., Malkawi, A., Alrefai, A., Khader, Y., Saadeh, R., & Saydam, M. (2011) · Muscle & Nerve · doi:10.1002/mus.22205 · Cited by 83
Patients' Perspectives on Nonadherence to Statin Therapy: A Focus-Group Study
Vicki, F., Sinclair, F., Wang, H., Dailey, D., Hsu, J., & Shaber, R. (2010) · The Permanente Journal · doi:10.7812/tpp/09-090 · Cited by 83 · cited 1×
“From a patient perspective, concerns about the adverse effects of statins are a dominant theme [26, 27].”
BackgroundLauridsen, B. K., Stender, S., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv108 · Cited by 81 · cited 6×
“FH is inherited as an autosomal dominant trait and is characterized by markedly elevated circulating levels of LDL-C from the time of birth as well as premature atherosclerotic CVD (ASCVD) [57–59].”
BackgroundInfluentialPhysicians’ Ability to Predict Patients’ Adherence to Antihypertensive Medication in Primary Care
ZELLER, A., TAEGTMEYER, A., MARTINA, B., BATTEGAY, E., & TSCHUDI, P. (2008) · Hypertension Research · doi:10.1291/hypres.31.1765 · Cited by 79 · cited 1×
“Using clinical judgment alone, physicians are poor at identifying which patients have problems with adherence [25].”
BackgroundPanta, R., Dahal, K. B., & Kunwar, S. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.12.006 · Cited by 77
Rhabdomyolysis in Association with Simvastatin and Amiodarone
Roten, L., Schoenenberger, R. A., Krähenbühl, S., & Schlienger, R. G. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d498 · Cited by 76 · cited 1×
“This was partially due to drug interactions with inhibitors of P450 cytochrome (CYP) 3A4, the main CYP involved in the hepatic metabolism of the lipophilic statins [49].”
BackgroundSelf-citationAdherence to lipid-lowering treatment: the patient perspective
Catapano, A. L., Casula, M., & Tragni, E. (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29092 · Cited by 67 · cited 1×
“From a patient perspective, concerns about the adverse effects of statins are a dominant theme [26, 27].”
BackgroundChallenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia
Ito, M. K., & Watts, G. F. (2015) · Drugs · doi:10.1007/s40265-015-0466-y · Cited by 62 · cited 2×
“LDL-C levels in these patients are two- to threefold higher than normal [58, 59, 62, 63].”
BackgroundContrasting Cholesterol Management Guidelines for Adults with CKD
Colantonio, L. D., Baber, U., Banach, M., Tanner, R. M., Warnock, D. G., Gutiérrez, O. M., Safford, M. M., Wanner, C., Howard, G., & Muntner, P. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014040400 · Cited by 60 · cited 1×
“which has been a matter of debate [16, 17].”
BackgroundStatins and diabetes risk: how real is it and what are the mechanisms?
Robinson, J. G. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000172 · Cited by 58 · cited 1×
“the mevalonate–cholesterol pathway [131, 132].”
The genetics of familial hypercholesterolemia and emerging therapies
Vogt, A. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s44315 · Cited by 52
Fouchier, S. W., Sankatsing, R. R., Peter, J., Castillo, S., Pocovi, M., Alonso, R., Kastelein, J. J. P., & Defesche, J. C. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.029454 · Cited by 47 · cited 1×
“Quite the opposite, they appear to dramatically reduce the risk of myocardial infarction [128, 129].”
BackgroundVishwanath, R. L., & Hemphill, L. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.11.002 · Cited by 41 · cited 2×
“LDL-C levels in these patients are two- to threefold higher than normal [58, 59, 62, 63].”
BackgroundSkoumas, J., Liontou, C., Chrysohoou, C. A., Masoura, C., Aznaouridis, K. A., Pitsavos, C., & Stefanadis, C. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.08.047 · Cited by 41
Rahman Chowdhury, S. (2021) · Journal of Endocrinology and Thyroid Research · doi:10.19080/jetr.2021.05.555674 · Cited by 40
Novel Therapies Focused on the High-Density Lipoprotein Particle
van Capelleveen, J. C., Brewer, H. B., Kastelein, J. J. P., & Hovingh, G. K. (2014) · Circulation Research · doi:10.1161/circresaha.114.301804 · Cited by 37 · cited 1×
“CETP inhibitors have been developed, five of which have been or currently are in different stages of clinical investigation [120].”
BackgroundLomitapide for homozygous familial hypercholesterolaemia
Raal, F. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61845-5 · Cited by 37
Spinler, S. A., Cziraky, M. J., Willey, V. J., Tang, F., Maddox, T. M., Thomas, T. F., Dueñas, G. G., & Virani, S. S. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.05.011 · Cited by 36 · cited 1×
“Goals were not achieved for nearly 70 % of patients [33].”
BackgroundTuteja, S., Duffy, D., Dunbar, R. L., Movva, R., Gadi, R., Bloedon, L. T., & Cuchel, M. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1351 · Cited by 36
Barkas, F., Liberopoulos, E. N., Kostapanos, M. S., Liamis, G. L., Tziallas, D., & Elisaf, M. (2014) · Angiology · doi:10.1177/0003319714535073 · Cited by 35 · cited 1×
“Despite treatment guideline recommendations, low achievement rates of LDL-C targets are reported, and a large proportion (10–20 %) of high-risk and very high-risk patients still do not meet their target, particularly those who are not receiving high-potency statins [39, 55, 56].”
BackgroundRodríguez, F., Olufade, T. O., Heithoff, K. A., Friedman, H. S., Navaratnam, P., & Foody, J. M. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.10.021 · Cited by 25 · cited 1×
“Despite treatment guideline recommendations, low achievement rates of LDL-C targets are reported, and a large proportion (10–20 %) of high-risk and very high-risk patients still do not meet their target, particularly those who are not receiving high-potency statins [39, 55, 56].”
BackgroundRobinson, J. G., Rogers, W. J., Nedergaard, B. S., Fialkow, J. A., Neutel, J. M., Ramstad, D., Somaratne, R. M., Legg, J. C., Nelson, P., Scott, R. C., et al. (2014) · Clinical Cardiology · doi:10.1002/clc.22252 · Cited by 19
Simko, V., & Ginter, E. (2014) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2014_013 · Cited by 11 · cited 3×
“Cholesterol is a natural component of the body’s metabolism: together with other lipids, it is an essential constituent of cell membranes and a constituent of steroid hormones, vitamin D, and bile acids [126].”
BackgroundInfluentialRaal, F. J., Kurtz, C. E., Honarpour, N., Tang, L., & Stein, E. A. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.221 · Cited by 10
Sattar, N. A., Preiss, D., Blom, D. J., Djedjos, C. S., Elliott, M., Pellacani, A. U. E., Wasserman, S. M., Koren, M. J., & Holman, R. R. (2015) · Diabetologia · Cited by 6
Thapa, R., Sharma, S., Jeevanantham, V., Hu, C., Myers, T., Vacek, J. L., Dawn, B., & Gupta, K. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.11.006 · Cited by 4 · cited 1×
“Additionally, disparities in lipid control among patients with T2DM using statins have been reported [32].”
Background
Research works printed but not linked: 6
- 1. European Cardiovascular Disease Statistics 2012 edition. http:// www.escardio.org/The-ESC/Initiatives/EuroHeart/2012-European- Cardiovascular-Disease-Statistics. Last accessed Jan 2016.
- 54. Golomb B, Yang E, Denenberg J, et al. Statin-associated muscle adverse effects. Circulation. 2003;107:e7028-9.
- 76. Dorey E. Cholesterol-busting PCSK9 drugs. Pharm J. 2015. http:// www.pharmaceutical-journal.com/news-and-analysis/features/ pcsk9-inhibitors-the-next-cholesterol-lowering-blockbusters/200 68181.article. Last accessed Jan 2016.
- 90. Ginsberg HN, Rader DJ, Raal FJ. ODYSSEY HIGH FH: effi- cacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia. Circulation. 2014;130:2119.
- 96. Roth E, Rader DJ, Moriarty P. Phase 3 randomized trial eval- uating alirocumab every four weeks dosing as add-on to statin or as monotherapy: ODYSSEY CHOICE I. Abstract no. 0254 presented at 17th International Symposium on Atherosclerosis. 2015.
- 97. Stroes E, Guyton J, Farnier M. Alirocumab in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study. Abstract no. 0269 presented at 17th Inter- national Symposium on Atherosclerosis. 2015.
Cited by
Wright, R. S., Ray, K. K., Raal, F. J., Kallend, D. G., Jaros, M., Koenig, W., Leiter, L. A., Landmesser, U., Schwartz, G. G., Friedman, A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.058 · Cited by 229
Mechanisms of statin-associated skeletal muscle-associated symptoms
Bouitbir, J., Sanvee, G. M., Panajatovic, M. V., Singh, F., & Krähenbühl, S. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.010 · Cited by 136
Self-citationAlleyne, C., Amin, R. P., Bhatt, B., Bianchi, E., Blain, J. C., Boyer, N., Branca, D., Embrey, M. W., Ha, S. N., Jette, K., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01084 · Cited by 131
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Amino Acids and Their Metabolism in Atherosclerosis
Nitz, K., Lacy, M., & Atzler, D. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311572 · Cited by 114
Metadata
- Authors
- Krähenbühl, S., Pavik-Mezzour, I., & von Eckardstein, A.
- Affiliations
- University of Basel (CH)
- Amgen (Switzerland) (CH)
- Corresponding author
- Krähenbühl, Stephan
- ORCID
- Krähenbühl, Stephan
- Venue
- Drugs
- Published
- 2016-07-25
- Volume
- 76
- Issue
- 12
- Pages
- 1175-1190
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- PMC
- PMC4974266
- OpenAlex
- W2496801530
- Semantic Scholar
- 7f30ae4aa52afa3ab98b84823e58b05b6cddea29
- Cited by
- 89
- References
- 121
- Citations by year
- 2026: 11 · 2025: 6 · 2024: 11 · 2023: 10 · 2022: 9 · 2021: 15 · 2020: 7 · 2019: 7 · 2018: 8 · 2017: 5
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc)
- edoc (University of Basel) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Funded by the institutions of the authors
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- LDL cholesterol lowering, statin therapy, statin adverse effects, statin-induced myopathy, familial hypercholesterolemia, ezetimibe, PCSK9 inhibitors, evolocumab, alirocumab, CETP inhibitors, combination therapy, cardiovascular risk reduction, hypercholesterolemia
- MeSH terms
- Ezetimibe, Cardiovascular Diseases, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Subtilisin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.